Innogen Pharmaceuticals has formalized a licensing agreement with Arcera Life Sciences, enabling Arcera to exclusively commercialize Efsubaglutide Alfa in selected countries across Africa, Latin America, the Middle East, and Eastern Europe. Innogen retains rights to the product in all other global markets.
Under the terms of the agreement, Innogen will receive $38 million in upfront and near-term milestone payments. This includes a non-refundable upfront payment of $15 million, supplemented by sales milestone payments and tiered royalties that may reach double-digit percentages based on aggregate annual net sales within the licensed territories. The total potential deal value is estimated to exceed $1 billion.
This collaboration represents a pivotal advancement in bringing a China-developed and commercialized innovative glucagon-like peptide-1 (GLP-1) therapy to international markets. It underscores Innogen’s commitment to expanding its global footprint and highlights the growing potential for China-originated pharmaceutical innovations to achieve international commercialization.
Arcera Life Sciences will leverage its expertise in regulatory affairs, market access, and commercialization to accelerate the development and distribution of Efsubaglutide Alfa within the licensed regions. Both companies aim to enhance patient access to novel treatment options for diabetes, obesity, and related metabolic diseases.
Efsubaglutide Alfa is a fusion protein combining a human GLP-1 analogue with an IgG Fc fragment, exhibiting an average half-life of up to 280 hours across various studies. Clinical data demonstrate that monotherapy with Efsubaglutide Alfa reduces HbA1c levels by 1.1 percentage points after four weeks, with reductions reaching up to 2.2 percentage points at 24 weeks. Additionally, the therapy may contribute to the protection of pancreatic beta-cell function.
The drug has shown promising potential in treating obesity and metabolic disorders. In the Phase IIb ENLIGHT study involving Chinese adults with overweight or obesity, participants receiving 20 mg once weekly for 18 weeks experienced an average body-weight reduction of 10.6% and a waist circumference decrease of approximately 8.9 cm. Those on a 20 mg dose every two weeks achieved a 9.7% average weight reduction.
Further analysis revealed improvements in body composition, including a muscle-to-fat ratio increase of up to 45.3% from baseline with weekly dosing. Weight loss was primarily due to fat mass reduction, with relative preservation of muscle mass. Liver fat content decreased by up to 51.8% with weekly dosing. The incidence of gastrointestinal adverse events was low compared to other GLP-1 receptor agonists, with no treatment discontinuations due to adverse events during the 18-week period, indicating good tolerability.
Innogen has also completed a Phase II clinical trial in Australia assessing the safety and efficacy of once-monthly dosing in adults with overweight or obesity. This study further supports the product’s potential for global registration and commercialization.
Dr. Qinghua Wang, Founder, Chairman, and CEO of Innogen Pharmaceuticals, stated: "We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen's international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen's mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide. Our collaboration with Arcera is an important step toward this vision. By combining Innogen's scientific innovation with Arcera's strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world."
Isabel Afonso, CEO of Arcera Life Sciences, commented: "Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners' scientific capabilities with Arcera's regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease."
Founded in 2014, Innogen Pharmaceuticals (HKEX: 2591) focuses on the research, development, and industrialization of innovative medicines for metabolic diseases. Its pipeline includes treatments for type 2 diabetes, type 1 diabetes, obesity, metabolic dysfunction-associated steatohepatitis, and Alzheimer's disease. Efsubaglutide Alfa, its core product, is a next-generation, human-derived, ultra-long-acting GLP-1 receptor agonist developed in-house. It is approved for type 2 diabetes treatment in mainland China and Macao and included in China's National Reimbursement Drug List (2025 version). The product’s development was supported by China’s 13th Five-Year Plan Major New Drug Innovation program and has received prestigious scientific awards.
Innogen Pharmaceuticals Licenses Efsubaglutide Alfa to Arcera Life Sciences for Strategic Global Market Expansion Innogen Pharmaceuticals has entered a licensing agreement with Arcera Life Sciences, granting exclusive rights to Efsubaglutide Alfa in select countries across Africa, Latin America, the Middle East, and Eastern Europe.... Read the full IIPLA article: https://iipla.org/news/innogen-pharmaceuticals-licenses-efsubaglutide-alfa-to-arcera-life-sciences-for-strategic-global-market-expansion